LUNG CANCER (NSCLC)

This study is testing a new medicine called PF-08634404 for adults with early-stage or locally advanced non-small cell lung cancer. Researchers want to see if the drug works better when given alone or with chemotherapy, either before surgery or after other treatments. The trial w…

This study is testing whether adding a new drug called capivasertib to a standard lung cancer drug (osimertinib) can help control advanced non-small cell lung cancer that has specific genetic changes and has started growing again after initial treatment. It will involve about 53 …

This study is testing a new drug called ivonescimab for people with advanced non-small cell lung cancer that has specific genetic changes and has stopped responding to standard treatments. It will test the drug by itself in one group of patients, and combined with standard chemot…

This study looks back at the real-world use of the drug IBI351 in 600 Chinese patients with a specific, hard-to-treat form of advanced lung cancer (KRAS G12C mutation). The main goal is to see how well the drug worked in everyday clinical practice and how safe it was for patients…

This study aims to improve the precision of radiation therapy for lung cancer by better tracking how tumors move when patients breathe. Researchers will combine a special MRI scan taken before treatment with X-ray images taken during treatment to create a more accurate motion mod…

This study is testing a new combination of drugs given before and after surgery for patients with a specific genetic type of lung cancer (called KRAS G12C). The goal is to see if this approach can shrink or eliminate the cancer in the tumor before it's removed and prevent it from…

This early-stage study is testing a new cell-based treatment called SL-28 in adults with advanced solid tumors that have not responded to standard therapies. The main goals are to find the safest and most effective dose and to check for side effects. Participants will receive the…

This study aims to find the better treatment for people with early-stage lung cancer who are at high risk for surgery. It will compare a minimally invasive surgical procedure to a targeted form of radiation therapy. The main goal is to see which treatment helps patients live long…

This study is testing a new combination of drugs (tunlametinib plus others) for people with advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation and has stopped responding to standard treatments. It aims to see if this combination can shri…

This study is testing whether giving an immunotherapy drug called cemiplimab before and after surgery can help people with early-stage lung cancer. It will enroll 33 patients whose cancer has a specific marker (PD-L1 ≥50%). The main goal is to see how much cancer is left in the t…

This study is testing a new type of PET scan that detects a protein called PD-L1 in tumors. Researchers want to see if this scan can identify which patients with lung cancer, melanoma, or other solid tumors are most likely to benefit from immunotherapy drugs. The scan uses a radi…

This study aims to find the best way to measure if rehabilitation helps people with advanced lung cancer whose disease is stable after treatment. About 63 participants will join a 3-month physical activity program. Researchers will check if the program improves their quality of l…

This study is testing whether a special PET scan using a radioactive tracer can show how much of the tracer collects in lung cancer tumors with HER2 abnormalities. Researchers want to see if tumors with HER2 mutations collect the tracer differently than tumors that just have high…

This study aims to use artificial intelligence (AI) to predict how well patients' lungs will recover after surgery for early-stage lung cancer. Researchers will combine 3D lung scans and breathing test results to create a predictive score. They will compare recovery between three…

This study aims to understand why some lung cancer patients respond well to immunotherapy drugs while others do not. Researchers will collect and analyze sputum (mucus from the lungs) and blood samples from 50 patients before and during their standard immunotherapy treatment. The…

This study looks back at data from 1,000 past lung cancer patients to see if artificial intelligence (AI) can better predict outcomes. The AI analyzes patients' CT scans, tissue samples, and genetic test results to learn which patients are most likely to stay cancer-free after su…